Viz-hcm
1 paper2 findings
- 1 lab in 1 country
- Humans1
Outcomes
2Time to SCD risk stratification
downin humans1
1 study
Time to SCD risk stratification
downin humans1
Viz-hcm decreases time to SCD risk stratification in humans.
“Similarly, the timeline for developing individualized SCD risk stratification profiles was significantly shortened.”
Human trialNovember 2024 to March 25, 2025n = 48
AHA Scientific Sessions 2025 abstract3 Nov 2025
Time to diagnosis
downin humans1
1 study
Time to diagnosis
downin humans1
Viz-hcm decreases time to diagnosis in humans (mean of 37 days).
“Time from EKG flag to diagnostic confirmation was reduced from years—as noted in historical literature—to a mean of 37 days.”
Human trialNovember 2024 to March 25, 2025n = 48
AHA Scientific Sessions 2025 abstract3 Nov 2025
Latest
1 in 12 monthsAHA Scientific Sessions 2025 Abstract
Improving Early Detection of Hypertrophic Cardiomyopathy Using Viz-HCM: A Quality Improvement Initiative Leveraging Artificial Intelligence-Assisted EKG HCM Screening
Study of 48 peopleHypertrophic cardiomyopathy